Annual Accounts Payable
$3.20 M
+$719.70 K+29.03%
April 30, 2024
Summary
- As of February 8, 2025, IPA annual accounts payable is $3.20 million, with the most recent change of +$719.70 thousand (+29.03%) on April 30, 2024.
- During the last 3 years, IPA annual accounts payable has risen by +$746.30 thousand (+30.43%).
- IPA annual accounts payable is now -13.18% below its all-time high of $3.68 million, reached on April 30, 2022.
Performance
IPA Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$3.87 M
+$393.10 K+11.31%
October 31, 2024
Summary
- As of February 8, 2025, IPA quarterly accounts payable is $3.87 million, with the most recent change of +$393.10 thousand (+11.31%) on October 31, 2024.
- Over the past year, IPA quarterly accounts payable has increased by +$393.10 thousand (+11.31%).
- IPA quarterly accounts payable is now at all-time high.
Performance
IPA Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
IPA Accounts Payable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +29.0% | +11.3% |
3 y3 years | +30.4% | +11.3% |
5 y5 years | +170.0% | +11.3% |
IPA Accounts Payable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -13.2% | +30.4% | at high | +123.0% |
5 y | 5-year | -13.2% | +170.0% | at high | +427.3% |
alltime | all time | -13.2% | >+9999.0% | at high | >+9999.0% |
ImmunoPrecise Antibodies Accounts Payable History
Date | Annual | Quarterly |
---|---|---|
Oct 2024 | - | $3.87 M(+11.3%) |
Jul 2024 | - | $3.48 M(+8.7%) |
Apr 2024 | $3.20 M(+29.0%) | $3.20 M(-10.6%) |
Jan 2024 | - | $3.58 M(+20.3%) |
Oct 2023 | - | $2.97 M(+10.8%) |
Jul 2023 | - | $2.68 M(+8.2%) |
Apr 2023 | $2.48 M(-32.7%) | $2.48 M(-22.9%) |
Jan 2023 | - | $3.21 M(-9.1%) |
Oct 2022 | - | $3.54 M(+103.8%) |
Jul 2022 | - | $1.74 M(-52.9%) |
Apr 2022 | $3.68 M(+50.2%) | $3.68 M(+42.6%) |
Jan 2022 | - | $2.58 M(-11.0%) |
Oct 2021 | - | $2.90 M(+21.5%) |
Jul 2021 | - | $2.39 M(-2.7%) |
Apr 2021 | $2.45 M(+94.4%) | $2.45 M(+23.2%) |
Jan 2021 | - | $1.99 M(+22.0%) |
Oct 2020 | - | $1.63 M(-5.5%) |
Jul 2020 | - | $1.73 M(+36.9%) |
Apr 2020 | $1.26 M(+6.5%) | $1.26 M(+71.9%) |
Jan 2020 | - | $733.90 K(-10.8%) |
Oct 2019 | - | $822.80 K(-15.1%) |
Jul 2019 | - | $969.60 K(-18.1%) |
Apr 2019 | $1.18 M(-25.2%) | $1.18 M(-25.2%) |
Apr 2018 | $1.58 M(+1114.5%) | $1.58 M(+339.7%) |
Jan 2018 | - | $360.20 K(+156.9%) |
Oct 2017 | - | $140.20 K(-44.9%) |
Jan 2017 | - | $254.60 K(+78.9%) |
Sep 2016 | - | $142.30 K(+10.7%) |
Jun 2016 | - | $128.60 K(-9.6%) |
Mar 2016 | - | $142.30 K(+9.1%) |
Dec 2015 | $130.40 K(-16.2%) | - |
Dec 2015 | - | $130.40 K(+5.6%) |
Sep 2015 | - | $123.50 K(-7.4%) |
Jun 2015 | - | $133.30 K(-9.1%) |
Mar 2015 | - | $146.60 K(-5.8%) |
Dec 2014 | $155.60 K(-8.3%) | - |
Dec 2014 | - | $155.60 K(-10.2%) |
Sep 2014 | - | $173.20 K(+11.7%) |
Jun 2014 | - | $155.10 K(+4.2%) |
Mar 2014 | - | $148.80 K(-12.3%) |
Dec 2013 | $169.60 K(-21.7%) | - |
Dec 2013 | - | $169.60 K(-11.9%) |
Sep 2013 | - | $192.50 K(+0.8%) |
Jun 2013 | - | $190.90 K(+6.8%) |
Mar 2013 | - | $178.70 K(-17.5%) |
Dec 2012 | $216.70 K(+35.6%) | - |
Dec 2012 | - | $216.70 K(-10.2%) |
Sep 2012 | - | $241.30 K(+40.0%) |
Jun 2012 | - | $172.30 K(-5.8%) |
Mar 2012 | - | $182.90 K(+14.5%) |
Dec 2011 | $159.80 K(+45.0%) | - |
Dec 2011 | - | $159.80 K(-10.0%) |
Sep 2011 | - | $177.60 K(+61.2%) |
Dec 2010 | $110.20 K | - |
Date | Annual | Quarterly |
---|---|---|
Dec 2010 | - | $110.20 K(-15.4%) |
Sep 2010 | - | $130.30 K(+28.0%) |
Jun 2010 | - | $101.80 K(+88.9%) |
Sep 2009 | - | $53.90 K(+11.4%) |
Jun 2009 | - | $48.40 K(-86.3%) |
Sep 2008 | - | $353.30 K(+369.8%) |
Jun 2008 | - | $75.20 K(+158.4%) |
Mar 2008 | - | $29.10 K(-14.9%) |
Dec 2007 | $34.20 K(-90.4%) | - |
Dec 2007 | - | $34.20 K(+18.8%) |
Sep 2007 | - | $28.80 K(-50.6%) |
Jun 2007 | - | $58.30 K(-56.8%) |
Mar 2007 | - | $135.00 K(-61.9%) |
Dec 2006 | $354.70 K(+206.8%) | - |
Dec 2006 | - | $354.70 K(-29.0%) |
Sep 2006 | - | $499.90 K(+1003.5%) |
Jun 2006 | - | $45.30 K(+6.3%) |
Mar 2006 | - | $42.60 K(-63.1%) |
Dec 2005 | $115.60 K(+194.1%) | - |
Dec 2005 | - | $115.60 K(-79.7%) |
Sep 2005 | - | $568.90 K(+130.2%) |
Jun 2005 | - | $247.10 K(+764.0%) |
Mar 2005 | - | $28.60 K(-27.2%) |
Dec 2004 | $39.30 K(+2.3%) | - |
Dec 2004 | - | $39.30 K(-59.4%) |
Sep 2004 | - | $96.80 K(+493.9%) |
Jun 2004 | - | $16.30 K(-29.4%) |
Mar 2004 | - | $23.10 K(-39.8%) |
Dec 2003 | $38.40 K(+174.3%) | - |
Dec 2003 | - | $38.40 K(-28.2%) |
Sep 2003 | - | $53.50 K(+119.3%) |
Jun 2003 | - | $24.40 K(+320.7%) |
Mar 2003 | - | $5800.00(-58.6%) |
Dec 2002 | $14.00 K(-24.7%) | - |
Dec 2002 | - | $14.00 K(+17.6%) |
Sep 2002 | - | $11.90 K(-26.5%) |
Jun 2002 | - | $16.20 K(-78.4%) |
Mar 2002 | - | $75.00 K(+303.2%) |
Dec 2001 | $18.60 K(-83.8%) | - |
Dec 2001 | - | $18.60 K(+154.8%) |
Sep 2001 | - | $7300.00(-73.7%) |
Jun 2001 | - | $27.80 K(-52.2%) |
Mar 2001 | - | $58.10 K(-49.3%) |
Dec 2000 | $114.60 K(+1537.1%) | - |
Dec 2000 | - | $114.60 K(+103.6%) |
Sep 2000 | - | $56.30 K(+256.3%) |
Jun 2000 | - | $15.80 K(+45.0%) |
Mar 2000 | - | $10.90 K(+55.7%) |
Dec 1999 | $7000.00(-69.7%) | - |
Dec 1999 | - | $7000.00(-69.7%) |
Dec 1998 | $23.10 K(-50.5%) | - |
Dec 1998 | - | $23.10 K(-50.5%) |
Dec 1997 | $46.70 K(-41.5%) | - |
Dec 1997 | - | $46.70 K |
Dec 1996 | $79.80 K | - |
FAQ
- What is ImmunoPrecise Antibodies annual accounts payable?
- What is the all time high annual accounts payable for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies annual accounts payable year-on-year change?
- What is ImmunoPrecise Antibodies quarterly accounts payable?
- What is the all time high quarterly accounts payable for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies quarterly accounts payable year-on-year change?
What is ImmunoPrecise Antibodies annual accounts payable?
The current annual accounts payable of IPA is $3.20 M
What is the all time high annual accounts payable for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high annual accounts payable is $3.68 M
What is ImmunoPrecise Antibodies annual accounts payable year-on-year change?
Over the past year, IPA annual accounts payable has changed by +$719.70 K (+29.03%)
What is ImmunoPrecise Antibodies quarterly accounts payable?
The current quarterly accounts payable of IPA is $3.87 M
What is the all time high quarterly accounts payable for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high quarterly accounts payable is $3.87 M
What is ImmunoPrecise Antibodies quarterly accounts payable year-on-year change?
Over the past year, IPA quarterly accounts payable has changed by +$393.10 K (+11.31%)